ABC-03: A randomized phase II trial of cediranib (AZD2171) or placebo in combination with cisplatin/gemcitabine (CisGem) chemotherapy for patients (pts) with advanced biliary tract cancer (ABC)

Authors :: Anthony Maraveyas
David Alan Anthoney
David Cunningham
William P. Steward
John Bridgewater
Charlotte Rees
Marian Duggan
Juan W. Valle
Srinivasan Madhusudan
Paul Ross
Justin S. Waters
Mark Jitlal
Harpreet Wasan
Philippa Corrie
Caroline Dive
Daniel H. Palmer
Alison Backen
Sandy Beare
Source :: Journal of Clinical Oncology. 32:4002-4002
Publication Year :: 2014
Publisher :: American Society of Clinical Oncology (ASCO), 2014.
Abstract: 4002 Background: ABCs exhibit increased VEGF expression, correlating with metastatic disease. Combining cediranib (which inhibits VEGFR1, 2 and 3 tyrosine kinase and VEGF-induced signaling in endot...

Subjects :: Oncology
Cancer Research
medicine.medical_specialty
Chemotherapy
Biliary tract cancer
Kinase
business.industry
medicine.medical_treatment
3-TYROSINE
Vegf expression
Placebo
Cediranib
Internal medicine
medicine
Cisplatin/gemcitabine
business
medicine.drug

Full Text Access

Tools